Journal of Thyroid Research / 2012 / Article / Tab 1

Clinical Study

Changes of TSH-Stimulation Blocking Antibody (TSBAb) and Thyroid Stimulating Antibody (TSAb) Over 10 Years in 34 TSBAb-Positive Patients with Hypothyroidism and in 98 TSAb-Positive Graves’ Patients with Hyperthyroidism: Reevaluation of TSBAb and TSAb in TSH-Receptor-Antibody (TRAb)-Positive Patients

Table 1

Changes of TSBAb (TSH-stimulation blocking antibody) and TSAb (thyroid stimulating antibody) over 10 years in 34 TSBAb-positive patients with hypothyroidism and in 98 TSAb-positive Graves’ patients with hyperthyroidism.

(I) 34 TSBAb-positive patients with hypothyroidism34

Ia: Positive TSBAb persistedContinued to have hypothyroidism1717
Ib: TSBAb disappearedIb1: Recovered from hypothyroidism1315
Ib2: Continued to have hypothyroidism2
Ic: TSBAb → TSAbTSBAb-positive hypo → Graves’ hyper22

(II) 98 TSAb-positive Graves’ patients with hyperthyroidism98

IIa: Positive TSAb persistedContinued to have Graves’ hyperthyroidism1010
IIb: Complex changes of TSAbIIb1: Remission113
IIb2: Recurrence12
IIc: TSAb disappearedIIc1: Remission6073
IIc2: Recurrence13
IId: TSAb → TSBAbGraves’ hyper → TSBAb-positive hypo22

Numbers of the patients are shown.
Serial changes of TSBAb and TSAb over 10 years were studied in 34 TSBAb-positive patients with hypothyroidism (I) and in 98 TSAb-positive Graves’ patients with hyperthyroidism (II). The 34 TSBAb-positive patients with hypothyroidism were treated with thyroxine (T4) and the 98 TSAb-positive Graves’ patients with hyperthyroidism were treated with antithyroid drugs (ATDs). Half (17) (Ia) of the 34 TSBAb-positive patients with hypothyroidism (I) continued to have positive TSBAb and continued to have hypothyroidism. Ten (IIa) of the 98 TSAb-positive Graves’ patients with hyperthyroidism (II) continued to have positive TSAb and continued to have Graves’ hyperthyroidism. With the disappearance of TSBAb, recovery from hypothyroidism was noted in 13 (Ib1) (87%) of the 15 patients, in whom TSBAb had disappeared (Ib). With the disappearance of TSAb, remissions of Graves’ hyperthyroidism were noted in 60 (IIc1) (82%) of the 73, in whom TSAb had disappeared (IIc). Two of the 34 TSBAb-positive patients with hypothyroidism developed TSAb-positive Graves’ hyperthyroidism (Ic), and two of the 98 TSAb-positive Graves’ patients with hyperthyroidism developed TSBAb-positive hypothyroidism (IId).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.